# Cardiology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Benny Leonard (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX008-SYN-TD
- Date: 1946-05-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Daniel Achebe-Lindqvist, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Miriam Okafor-Rosenthal, MD

## Reason for consultation

A 50-year-old professional boxing referee and boxing instructor with newly found stage 2 hypertension, left ventricular hypertrophy by voltage on the ECG, and two months of breathlessness and chest tightness late in long nights of refereeing in hot arenas. Please evaluate the symptoms and the hypertrophy, advise on his coronary and sudden cardiac death risk, and say whether and how he can keep refereeing. **S**

## History

Mr. Leonard, 50, a professional boxing referee and boxing instructor, is seen at the request of Dr. Okafor-Rosenthal two weeks after stage 2 hypertension was found at his license examination. For about two months he has had breathlessness and chest tightness late in long nights of refereeing in hot arenas, easing with a few minutes' rest; none at rest, no fainting or palpitations. Since starting losartan-hydrochlorothiazide two weeks ago he has refereed only undercards and has had no symptoms. He never smoked. His family history is not known. He asked whether he will lose his license. **S**

## Examination

| System | Finding |
|---|---|
| General | Lean, fit-looking man; blood pressure 148/92 mmHg, pulse 74 and regular |
| Cardiac | Sustained, undisplaced apex beat; fourth heart sound; no murmur at rest, with Valsalva or on standing; no rub |
| Vascular | No carotid or femoral bruits; foot pulses normal; no radio-femoral delay |
| Lungs and extremities | Clear lungs; no edema |

BP 148/92 mmHg; pulse 74 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 74.4 kg; BMI 27.3 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Okafor-Rosenthal's intake note, ECG and laboratory tests. Home readings over the past week averaged 146/92 mmHg. Basic metabolic panel today: sodium 139, potassium 4.0 mmol/L, creatinine 1.04 mg/dL. Transthoracic echocardiogram today: concentric left ventricular hypertrophy (septum 13 mm, posterior wall 12 mm, mass index 118 g/m2), ejection fraction 62%, grade 1 diastolic dysfunction, left atrial volume index 36 mL/m2, no systolic anterior motion or outflow obstruction at rest or with Valsalva, normal valves and aortic root. Exercise stress echocardiogram today (Bruce): 9 minutes 30 seconds, about 10.5 METs, peak heart rate 156 per minute (92% of predicted), blood pressure 150/92 rising to 226/98 mmHg, mild breathlessness at peak without chest discomfort, no ST change, no arrhythmia, normal wall augmentation. Coronary calcium CT today: Agatston 186 (left anterior descending 118, right coronary 52, circumflex 16), about the 80th percentile for his age and sex. Sodium: 139 mmol/L; Potassium: 4 mmol/L; Urea nitrogen: 16 mg/dL; Creatinine: 1.04 mg/dL; eGFR: 87 mL/min/1.73 m²; Glucose: 94 mg/dL; Left ventricular ejection fraction (echocardiogram): 62%; Interventricular septal thickness in diastole (echocardiogram): 13 mm (high); Left ventricular mass index (echocardiogram): 118 g/m2 (high); Left atrial volume index (echocardiogram): 36 mL/m² (high). All results are synthetic.

## Assessment

1. **Exertional breathlessness and chest tightness** (R06.09). Not ischemic. An exercise stress echocardiogram was chosen because it tests for ischemia, measures his working capacity and shows the blood pressure response to effort; it showed no inducible ischemia at about 10.5 METs. The symptoms are best explained by a steep rise in blood pressure on exertion (to 226/98 mmHg) in a thickened, stiff ventricle, made worse by heat; they should settle as blood pressure is controlled. **S**
2. **Type of hypertrophy** (I11.9). Hypertensive heart disease. The hypertrophy is concentric and modest (septum 13 mm, septal-to-posterior ratio 1.1) with no systolic anterior motion, no outflow gradient, a normal-sized cavity and diastolic dysfunction, in a man with stage 2 hypertension; this fits hypertension and not hypertrophic cardiomyopathy, and an athlete's heart is unlikely at 50 years and years after competitive training. If the hypertrophy does not regress after six to twelve months of good control, or a family history emerges, cardiac MRI would be the next test. **S**
3. **Sudden cardiac death risk** (I11.9). Left ventricular hypertrophy raises the risk of sudden cardiac death, and controlling blood pressure lowers it as the hypertrophy regresses. He has no fainting, palpitations or arrhythmia on exercise, a normal ejection fraction and a normal QTc, so ambulatory ECG monitoring and an implantable defibrillator are not indicated; monitoring would be needed for palpitations or fainting. Potassium should be kept in the normal range on the diuretic. He should know the warning symptoms, and the venues where he works should have a defibrillator at ringside and staff trained in CPR. **S**
4. **Coronary calcium, statin and aspirin** (I25.10). A coronary calcium score of 186, above 100 and about the 80th percentile, shows coronary atherosclerosis and favors a statin: atorvastatin 40 mg, aiming for LDL below 70 mg/dL and a fall of at least 50%, with a lipid panel at eight to twelve weeks. Low-dose aspirin may be considered with a score over 100, but not while blood pressure is uncontrolled because of the bleeding risk; it should be revisited as a shared decision once blood pressure is at goal. Routine repeat stress testing is not recommended without new symptoms. **S**
5. **Refereeing** (I11.9). He can keep refereeing. Until home blood pressure is below 140/90 mmHg, short undercards only; then full cards. Drink water between bouts, especially in hot arenas; stop and hand over a bout for chest discomfort, faintness or palpitations; hold the blood pressure tablet on sick days. A thiazide can deplete salt and water in a man who sweats heavily at work; if that happens, losartan with amlodipine is a good alternative. The target is below 130/80 mmHg, and the dose of losartan-hydrochlorothiazide can be raised at the next review if he is not there. **S**

## Recommendations

1. Continue losartan 50 mg with hydrochlorothiazide 12.5 mg; raise the dose if home readings stay above 130/80 mmHg; basic metabolic panel after each change.
2. If the thiazide causes volume depletion or low potassium in the heat, change to losartan with amlodipine.
3. Atorvastatin 40 mg each evening; lipid panel at eight to twelve weeks; LDL goal below 70 mg/dL.
4. No aspirin until blood pressure is controlled; then revisit it as a shared decision.
5. No ambulatory ECG monitoring or defibrillator now; monitoring for any palpitations or fainting; no routine repeat stress testing.
6. Short undercards until home blood pressure is below 140/90 mmHg, then full cards, with water between bouts and the warning symptoms explained; a defibrillator and CPR-trained staff at ringside.
7. Repeat echocardiogram six to twelve months after today to judge regression; cardiac MRI if the hypertrophy does not regress.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Okafor-Rosenthal, who saw him the same day. Mr. Leonard was told that his heart arteries are not narrowed enough to cause his symptoms, that the thickened heart muscle comes from high blood pressure and should improve with treatment, and that he can keep refereeing with the plan above. He was relieved, and asked that the medicines be generics he can afford; all three suggested are. **S**

## Follow-up

Cardiology review with the repeat echocardiogram in six to twelve months, or sooner for palpitations, fainting or new chest symptoms; Dr. Okafor-Rosenthal continues his blood pressure care. **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation 2023;148(9):e9-e119)
- 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain (2021), American Heart Association and American College of Cardiology (Circulation 2021;144(22):e368-e454)
- 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia (2026), American College of Cardiology and American Heart Association (Circulation 2026;153(17):e1154-e1276)
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease (2019), American College of Cardiology and American Heart Association (Circulation 2019;140(11):e596-e646)
- Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension (2015), American Heart Association and American College of Cardiology (Circulation 2015;132(22):e298-e302)
